Background: Despite therapeutic advances, vulvovaginal candidiasis remains a common problem worldwide, affecting all strata of society. Vulvovaginal candidiasis (VVC) is very common and a frequent cause of vaginosis. It has a high prevalence. A randomized controlled trial of topical clotrimazole versus oral fluconazole for treatment of vulvovaginal candidiasis was done at Aminu Kano Teaching Hospital between 30th December, 2011 and 23 rd February, 2012. Ethical approval for the research was obtained from the ethical committee of Aminu Kano Teaching Hospital Objective: To determine the more effective anti-candidal agent between topical clotrimazole and oral fluconazole in Aminu Kano Teaching Hospital (AKTH). Method: This was a prospective study of 300 patients who presented at the gynaecologic and general outpatients clinics of AKTH with clinical and laboratory evidence of vulvovaginal candidiasis who fulfilled the inclusion criteria. A subset of the study population (group A) comprising 150 subjects received topical clotrimazole 200mg intravaginally at bedtime for 3 days. Another subset (group B) comprising 150 subjects received fluconazole capsule 150mg statim. Research structured questionnaires were administered to all the 300 subjects before and after treatment. These gave various sociodemographic and clinical information. At the test-of-cure visit, clinical history and vaginal examination were carried out. Symptoms/signs numerical score after treatment was compared to the score at entry. The data obtained was analyzed using SPSS version 16.0 statistical software. Statistical significance of differences between means was determined using ANOVA. Significant association between sociodemographic factors and vulvovaginal candidiasis were tested using chi-square test and p<0.05 was considered significant.